Clinical Trial Results:
Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE)
Summary
|
|
EudraCT number |
2013-002114-12 |
Trial protocol |
CZ LT BE ES SE FI SK GR NO IT AT BG Outside EU/EEA FR HU DK DE |
Global end of trial date |
14 Nov 2019
|
Results information
|
|
Results version number |
v3(current) |
This version publication date |
14 Nov 2021
|
First version publication date |
28 May 2020
|
Other versions |
v1 , v2 |
Version creation reason |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
1160.106
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01895777 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Boehringer Ingelheim
|
||
Sponsor organisation address |
Dr. Boehringer-Gasse 5-11, Vienna, Austria, 1121
|
||
Public contact |
Boehringer Ingelheim, Call Center, Boehringer Ingelheim, 001 8002430127, clintriage.rdg@boehringer-ingelheim.com
|
||
Scientific contact |
Boehringer Ingelheim, Call Center, Boehringer Ingelheim, 001 8002430127, clintriage.rdg@boehringer-ingelheim.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-000081-PIP01-11 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
18 Dec 2019
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
16 Oct 2019
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
14 Nov 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The 2 main objectives were to assess the efficacy and safety of dabigatran etexilate (DE) relative to standard of care (SoC) and to document the appropriateness of the proposed DE dosing algorithm
|
||
Protection of trial subjects |
Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. Rescue medication was allowed for all patients as required.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
18 Feb 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 3
|
||
Country: Number of subjects enrolled |
Austria: 4
|
||
Country: Number of subjects enrolled |
Belgium: 6
|
||
Country: Number of subjects enrolled |
Brazil: 6
|
||
Country: Number of subjects enrolled |
Canada: 32
|
||
Country: Number of subjects enrolled |
Czechia: 54
|
||
Country: Number of subjects enrolled |
Denmark: 1
|
||
Country: Number of subjects enrolled |
Finland: 3
|
||
Country: Number of subjects enrolled |
France: 1
|
||
Country: Number of subjects enrolled |
Germany: 12
|
||
Country: Number of subjects enrolled |
Greece: 2
|
||
Country: Number of subjects enrolled |
Hungary: 7
|
||
Country: Number of subjects enrolled |
Israel: 1
|
||
Country: Number of subjects enrolled |
Italy: 11
|
||
Country: Number of subjects enrolled |
Lithuania: 4
|
||
Country: Number of subjects enrolled |
Mexico: 3
|
||
Country: Number of subjects enrolled |
Norway: 5
|
||
Country: Number of subjects enrolled |
Russian Federation: 92
|
||
Country: Number of subjects enrolled |
Spain: 1
|
||
Country: Number of subjects enrolled |
Sweden: 6
|
||
Country: Number of subjects enrolled |
Switzerland: 4
|
||
Country: Number of subjects enrolled |
Taiwan: 1
|
||
Country: Number of subjects enrolled |
Thailand: 5
|
||
Country: Number of subjects enrolled |
Turkey: 21
|
||
Country: Number of subjects enrolled |
Ukraine: 6
|
||
Country: Number of subjects enrolled |
United States: 37
|
||
Worldwide total number of subjects |
328
|
||
EEA total number of subjects |
117
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
8
|
||
Infants and toddlers (28 days-23 months) |
40
|
||
Children (2-11 years) |
75
|
||
Adolescents (12-17 years) |
205
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
A multi-centre, open-label, randomised, parallel-group, active-controlled, non-inferiority trial of dabigatran etexilate (DE) versus standard of care (SoC) in children from birth to less than 18 years of age. | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||||
Blinding implementation details |
It was an open-label trial
|
||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Dabigatran etexilate | ||||||||||||||||||||||||||||||
Arm description |
Oral administration of dabigatran etexilate (DE) twice daily. Patients aged ≥8 years: age- and weight-adjusted DE dosing via capsules using 50 milligram (mg), 75 mg, 110 mg, and 150 mg capsules. Patients aged <8 years or for patients who cannot take capsules even if older than 8 (but <12 years of age): age- and weight-adjusted dosing via DE pellets. Patients aged <12 months: age- and weight-adjusted dosing via DE oral liquid formulation (OLF). | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Dabigatran etexilate
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Oral liquid, Capsule, Granules
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Oral administration of dabigatran etexilate (DE) twice daily. Patients aged ≥8 years: age- and weight-adjusted DE dosing via capsules using 50 milligram (mg), 75 mg, 110 mg, and 150 mg capsules. Patients aged <8 years or for patients who cannot take capsules even if older than 8 (but <12 years of age): age- and weight-adjusted dosing via DE pellets. Patients aged <12 months: age- and weight-adjusted dosing via DE oral liquid formulation (OLF).
|
||||||||||||||||||||||||||||||
Arm title
|
Standard of care | ||||||||||||||||||||||||||||||
Arm description |
Investigators decided on SoC treatment at time of randomisation: either low molecular weight heparin (LMWH) or vitamin K antagonists (VKA) or fondaparinux. | ||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Low molecular weight heparin (LMWH) or vitamin K antagonists (VKA) or fondaparinux.
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use, Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Investigators decided on SoC treatment at time of randomisation: either low molecular weight heparin (LMWH) or vitamin K antagonists (VKA) or fondaparinux.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: This table is based on the randomized set and not on the subjects enrolled |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Dabigatran etexilate
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Oral administration of dabigatran etexilate (DE) twice daily. Patients aged ≥8 years: age- and weight-adjusted DE dosing via capsules using 50 milligram (mg), 75 mg, 110 mg, and 150 mg capsules. Patients aged <8 years or for patients who cannot take capsules even if older than 8 (but <12 years of age): age- and weight-adjusted dosing via DE pellets. Patients aged <12 months: age- and weight-adjusted dosing via DE oral liquid formulation (OLF). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Standard of care
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Investigators decided on SoC treatment at time of randomisation: either low molecular weight heparin (LMWH) or vitamin K antagonists (VKA) or fondaparinux. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Dabigatran etexilate
|
||
Reporting group description |
Oral administration of dabigatran etexilate (DE) twice daily. Patients aged ≥8 years: age- and weight-adjusted DE dosing via capsules using 50 milligram (mg), 75 mg, 110 mg, and 150 mg capsules. Patients aged <8 years or for patients who cannot take capsules even if older than 8 (but <12 years of age): age- and weight-adjusted dosing via DE pellets. Patients aged <12 months: age- and weight-adjusted dosing via DE oral liquid formulation (OLF). | ||
Reporting group title |
Standard of care
|
||
Reporting group description |
Investigators decided on SoC treatment at time of randomisation: either low molecular weight heparin (LMWH) or vitamin K antagonists (VKA) or fondaparinux. |
|
||||||||||||||||||||||
End point title |
Composite primary endpoint | |||||||||||||||||||||
End point description |
The primary endpoint was the combined endpoint of the proportions of patients with: - Complete thrombus resolution - Freedom from recurrent VTE - Freedom from mortality related to VTE. The events outlined in the above combined primary endpoint were assessed by radiologists or other such qualified clinicians using an appropriate method such as ultrasound, echocardiography, venography, or CT scan, based on the location of the thrombus and the test used to perform the baseline assessment. The primary efficacy endpoint contained 3 components. Each component was evaluated separately, and only if the criteria for all 3 components were satisfied, the primary endpoint was considered achieved. The randomised set (RS) included all randomised patients in the treatment groups to which they were randomised, regardless whether they took trial medication
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Primary endpoint analysis | |||||||||||||||||||||
Statistical analysis description |
The primary analysis of the primary efficacy endpoint used the randomised set, following the intention-to-treat principle, based on adjudication-confirmed data. Age group was used as stratification factor using a Mantel-Haenszel type weighted average of differences.
|
|||||||||||||||||||||
Comparison groups |
Standard of care v Dabigatran etexilate
|
|||||||||||||||||||||
Number of subjects included in analysis |
267
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
[1] | |||||||||||||||||||||
P-value |
= 0.0001 [2] | |||||||||||||||||||||
Method |
Cochran-Mantel-Haenszel | |||||||||||||||||||||
Parameter type |
Difference in Rates | |||||||||||||||||||||
Point estimate |
-0.038
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
90% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-0.141 | |||||||||||||||||||||
upper limit |
0.066 | |||||||||||||||||||||
Notes [1] - Non-inferiority margin of 20% [2] - p-value for non-inferiority is actually <0.0001 |
|
|||||||||||||
End point title |
Freedom from major bleeding events (MBEs) | ||||||||||||
End point description |
Freedom from major bleeding events (MBEs), defined as either fatal bleeding, clinically overt bleeding associated with a decrease in haemoglobin of at least 20 g/L in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial or otherwise involves the central nervous system, or bleeding that requires intervention in an operating suite. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From first administration of trial medication until last administration of trial medication +6 days (residual effect period).
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Time-to-event analysis | ||||||||||||
Statistical analysis description |
Time-to-event endpoint using Kaplan-Meier estimates based on adjudication-confirmed data. Due to the low event rate of major bleeding, age group stratification was not considered.
|
||||||||||||
Comparison groups |
Dabigatran etexilate v Standard of care
|
||||||||||||
Number of subjects included in analysis |
266
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
Method |
Kaplan-Meier estimate | ||||||||||||
Parameter type |
Kaplan-Meier estimate of rate difference | ||||||||||||
Point estimate |
0
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.032 | ||||||||||||
upper limit |
0.032 |
|
||||||||||
End point title |
Freedom from thrombus progression at end of therapy compared with baseline | |||||||||
End point description |
Freedom from thrombus progression at end of therapy compared with baseline, based on adjudication-confirmed data. The randomised set (RS) included all randomised patients in the treatment groups to which they were randomised, regardless whether they took trial medication.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
All bleeding events | ||||||||||||||||||||||||
End point description |
The incidence of bleeding events including major bleeding events (MBEs), clinically relevant non-major (CRNM) bleeding, minor bleeding events, any bleeding events, and the incidence of the combined endpoint of major and CRNM bleeding events was presented, based on adjudication-confirmed data. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
From first administration of trial medication until last adminstration of trial medication +6 days (residual effect period).
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
Time-to-event analysis | ||||||||||||||||||||||||
Statistical analysis description |
Any bleeding events was analysed as time-to-event endpoint using a stratified Cox proportional hazard model with treatment as a covariate in the model and age group as the stratification factor. A pooling of age groups was performed as no events were observed in certain age group.
|
||||||||||||||||||||||||
Comparison groups |
Dabigatran etexilate v Standard of care
|
||||||||||||||||||||||||
Number of subjects included in analysis |
266
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
|||||||||||||||||||||||||
P-value |
= 0.6149 | ||||||||||||||||||||||||
Method |
Regression, Cox | ||||||||||||||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||||||||||||||
Point estimate |
1.145
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
90% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
0.736 | ||||||||||||||||||||||||
upper limit |
1.78 |
|
||||||||||
End point title |
All-cause mortality | |||||||||
End point description |
Patients being alive at the end of observational period will be censored for all-cause mortality at the date of patients’ last date known to be alive, or the date of data cut-off whichever comes first. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
From first administration of trial medication until last administration of trial medication +6 days (residual effect period).
|
|||||||||
|
||||||||||
Statistical analysis title |
Time-to-event analysis | |||||||||
Statistical analysis description |
All-cause mortality was analyzed as time-to-event endpoint using a stratified Cox proportional hazard model with treatment as a covariate in the model.
|
|||||||||
Comparison groups |
Dabigatran etexilate v Standard of care
|
|||||||||
Number of subjects included in analysis |
266
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
[3] | |||||||||
P-value |
= 0.9976 | |||||||||
Method |
Cox proportional hazard model | |||||||||
Parameter type |
Hazard ratio (HR) | |||||||||
Point estimate |
6.99
|
|||||||||
Confidence interval |
||||||||||
level |
90% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
0 | |||||||||
upper limit |
99999.99 | |||||||||
Notes [3] - The estimated point value is actually 69990000 with the according the 90% confidence interval of (0, infinity) |
|
|||||||||
End point title |
Steady state plasma concentrations after at least 3 days following any dabigatran etexilate dose adjustment [4] | ||||||||
End point description |
Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate after at least 3 days following any dabigatran etexilate dose adjustment. The pharmacokinetic set (PKS) included all patients treated with DE who had at least 1 evaluable PK measurement and had no protocol deviations relevant to the evaluation of PK endpoints. Only scheduled visits were considered.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
|
||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: For this end point only the Dabigatran etexilate group was defined for the statistical analysis. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Frequency of dose adjustment during the treatment phase | ||||||||||||||||||
End point description |
Frequency of dose adjustments (i.e. number of patients with dose adjustment), temporary and permanent discontinuation from therapy, and number of patients with laboratory monitoring requirements for dose. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
From first administration of trial medication until last administration of trial medication +6 days (residual effect period).
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Assessment of the acceptability of an age-appropriate formulation at end of therapy (Capsules) [5] | ||||||||||||||
End point description |
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire capsules: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire capsules: How acceptable was the DE treatment for the child? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Patients questionnaire capsules: Was taking the study capsules easy or difficult? The score is 1 (Very easy), 2 (easy), 3 (neither easy nor difficult), 4 (difficult) and 5 (very difficult). Scores refers to the end of treatment. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Assessment at the last study visit
|
||||||||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: For this end point only the Dabigatran etexilate group was defined for the statistical analysis. |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Assessment of the acceptability of an age-appropriate formulation at end of therapy (Pellets) [6] | ||||||||||||
End point description |
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire pallets: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire pellets: Do you think that spitting occurs? The score is 1 (Never), 2 (sometimes) and 3 (often). Scores refers to the end of treatment. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Assessment at the last study visit
|
||||||||||||
Notes [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: For this end point only the Dabigatran etexilate group was defined for the statistical analysis. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Assessment of the acceptability of an age-appropriate formulation at end of therapy (Oral liquid formulation - OLF) [7] | ||||||||||||||||
End point description |
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire flavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Investigator questionnaire unflavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire for flavoured and unflavoured OLF.: Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Scores refers to the end of treatment. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Assessment at the last study visit
|
||||||||||||||||
Notes [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: For this end point only the Dabigatran etexilate group was defined for the statistical analysis. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Steady state plasma concentrations of total dabigatran at visit 3 [8] | ||||||||
End point description |
Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate at visit 3. The pharmacokinetic set (PKS) included all patients treated with DE who had at least 1 evaluable PK measurement and had no protocol deviations relevant to the evaluation of PK endpoints. Only scheduled visits were considered.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
From the time of randomisation until visit 3
|
||||||||
Notes [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: For this end point only the Dabigatran etexilate group was defined for the statistical analysis. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Frequency of patients switching the type of anti-coagulation therapy including Dabigatran etexilate to standard of care treatment and switching from one standard of care treatment to another | |||||||||
End point description |
Frequency of patients switching the type of anti-coagulation therapy including Dabigatran etexilate (DE) to standard of care (SoC) treatment and switching from one standard of care treatment to another. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication. For DE arm, only the switch from DE to SoC was counted, while for the SoC arm, all switches among SoC treatments were counted.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
From first administration of trial medication until last administration of trial medication +6 days (residual effect period).
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
All components of the primary efficacy endpoint | ||||||||||||||||||
End point description |
Patients with VTE-related death occurring between randomisation to Day 84 + 7 days were considered as not meeting the endpoint. The presence of recurrent VTE(s) was examined throughout the trial, and only the date of first occurrence was used for analysis. Assessment of index VTE status (best overall response) was scheduled on Day 84 ± 7 days (Visit 8) for patients who were alive without an early consent withdraw. In the case a Patient discontinued trial medication prematurely due to any reason the index VTE assessment took place at the early end of treatment visit. The randomised set (RS) included all randomised patients in the treatment groups to which they were randomised, regardless whether they took trial medication
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
For DE patients all AEs recorded between first dabigatran etexilate (DE) intake until 6 days after the last administration of dabigatran etexilate. The Open-label treatment period with DE or SOC is from vist 2 defined as day 0 up to 84 days.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
For patients in standard of care arm, all AEs occurred between the first drug intake of standard of care (SOC) until 6 days after the last administration of any standard of care. The treated set (TS) includes all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Standard of care (SoC)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Investigators decided on SoC treatment at time of randomisation: either low molecular weight heparin (LMWH) or vitamin K antagonists (VKA) or fondaparinux. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Dabigatran etexilate
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Oral administration of dabigatran etexilate (DE) twice daily. Patients aged ≥8 years: age- and weight-adjusted DE dosing via capsules using 50 milligram (mg), 75 mg, 110 mg, and 150 mg capsules. Patients aged <8 years or for patients who cannot take capsules even if older than 8 (but <12 years of age): age- and weight-adjusted dosing via DE pellets. Patients aged <12 months: age- and weight-adjusted dosing via DE oral liquid formulation (OLF). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
02 Oct 2014 |
With Global Amendment 1, recruitment of patients with a body weight ≥40 kg was temporarily suspended. It was projected that, because of the performed capping of the maximum single starting dose at 220 mg, a considerable proportion of patients with a body weight ≥40 kg will have dabigatran plasma levels falling below 50 ng/mL. |
||
28 Jan 2015 |
The age cut-offs for stratum 2 and 3 were changed based on the EMA PDCO opinion dated 29 Sep 2014 .A twice daily dosing regimen using actual calculated dosages (according to Hayton equation) was implemented. It was clarified that patients aged 6 months to <8 years and those who cannot take capsule at an age of 8 to <12 years were to receive pellets, and that patients aged 0 to <6 months and those who cannot take pellets at an age of 6 to <12 months were to receive OLF. In the benefit-risk section of the CTP, information on the Phase IIa trials was updated as these trials were a prerequisite for opening the second age group (2 to <12 years). An additional exclusion criterion was introduced: Patients in age group 0 to <2 years with gestational age at birth <37 weeks or with a body weight lower than the 3rd percentile (according to the WHO Child growth standards) were not to be entered in the trial. It was clarified that all patients who continued treatment for VTE, regardless of whether this was a switch from DE to SoC or from one SoC to another, are not considered early discontinued. A more detailed and age-specific description of the blood sample volumes collected during the trial was added. |
||
26 Nov 2015 |
The up-titration dosing nomograms for capsules and pellets were updated to correct calculation errors. It was stated that the OLF dosing nomograms will need to be updated as well in advance of opening the youngest age group (0 to <2 years). |
||
16 Mar 2016 |
The assessment of thrombus extension at Visit 5 was removed from the CTP, to better reflect the clinical routine for follow-up of patients with VTE and to eliminate potential unwarranted radiation exposure. A summary of Phase I bioavailability trial 1160.194 was added to provide background information for considering DE formulations to be used interchangeable, without the need for a conversion factor. It was clarified that patients requiring VTE therapy beyond 3 months have to be switched at Visit 8 (Day 84) to SoC treatment (if randomised to DE) or continue SoC treatment (if randomised to the SoC arm) and could be treated with SoC during the follow-up period. Randomisation in a 1:1 ratio to an OLF with either a flavoured or an unflavoured solvent for reconstitution was introduced. It was clarified that eGFR retesting was allowed once during the screening period. The criterion when to remove patients from the trial because of low eGFR was decreased to <50 mL/min/1.73m². The 150 mg DE capsule was introduced to reduce the number of capsules taken by patient at a single time point. It was explained that in case of gastrointestinal symptoms, DE was to be taken with a meal or concomitantly with a proton pump inhibitor. In the inclusion criteria, it was added that a temporary interruption of the anticoagulant therapy for the index VTE event or prior to the start of secondary VTE prophylaxis was acceptable, if one of the defined pre-requisites was met. |
||
29 Nov 2016 |
The sample size was reduced from a minimum of 240 to a minimum of 180 evaluable patients for the efficacy component of the co-primary endpoint. The duration of the follow-up period was reduced from 9 months to 1 month after the last intake of trial medication. It was clarified that freedom from thrombus progression at the end of therapy (Day 84 after randomisation or eEOT whichever comes first) will be assessed in comparison with baseline. It was clarified that pre-treatment with VKAs during the initial parenteral treatment was acceptable if the INR had not reached a therapeutic level (INR <2.0) at the time of randomisation. To facilitate an expedited evaluation of the risk of bleeding in patients <2 months of age, the first trough dabigatran concentration assessment (at Visit 3) was required to be supplemented by a local aPTT measurement for patients <2 months and a baseline aPTT was also required to be available for these patients. The final results of the completed Phase IIa PK/PD trials relevant for the patients to be included in second age group (2 to<12 years) and in youngest age group (0 to <2 years) were provided. The eGFR threshold for exclusion from the trial was changed to <60 mL/min/1.73m2 for patients aged 12 to <18 years. The recommendation to use a proton pump inhibitor such as pantoprazole in case of development of gastrointestinal symptoms was replaced by the recommendation to use a proton pump inhibitor according to the local SoC in accordance with local labelling recommendations. To reflect the sequential introduction of age appropriate formulations (and OLF in particular), it was clarified that patients in age group 2 to <12 years are to be entered and treated considering the availability of the age appropriate DE formulations. The analysis set for PK analyses was defined. It was clarified that interim analyses based on selected or partial clinical trial data may be conducted for regulatory purposes. |
||
30 Oct 2017 |
The sample size was further reduced from a minimum of 180 to a minimum of 141 evaluable patients for the efficacy primary endpoint, but it was clarified that the recruitment of further patients could be continued if required by regulatory authorities. Based on FDA advice, freedom from major bleeding events was changed from the coprimary safety endpoint to a secondary endpoint. Fondaparinux was added as allowed SoC treatment based on therapeutic guidelines and EMA advice. The flow chart was amended with several clarifications regarding visit windows, the collection of post-dose samples, and follow-up periods. |
||
16 Jan 2018 |
Active meningitis, encephalitis, and intracranial abscess at Visit 2 were added as exclusion criteria. Furthermore, patients who developed active meningitis, encephalitis, or intracranial abscess were to be discontinued from the trial medication. |
||
11 Sep 2018 |
The option to administer pellets was expanded to patients <6 months of age. A preference for usage of OLF over pellets in patients <12 months of age, provided that OLF supplies are available to the site, was implemented. The time window from Visit 1 (screening) to Visit 2 (first administration of trial medication)was expanded to 21 days to facilitate screening procedures. It was clarified that the discontinuation from trial medication is required if a drug-related SAE occurred. It was added that the type of SoC may be changed during the treatment period in patients randomised to SoC. The wording of several secondary endpoints was modified to clarify the meaning |
||
06 Feb 2019 |
The eGFR threshold in exclusion criterion 2 was lowered to <50 mL/min/1.73 m² for all patients, irrespective of their age. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |